18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth


  • Mine Araz
  • Derya Çayır

Received Date: 12.07.2016 Accepted Date: 26.08.2016 Mol Imaging Radionucl Ther 2017;26(1):1-8 PMID: 28291004

Positron emission tomography/computed tomography (PET/CT) with [sup]18[/sup]F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of [ref:18]18[/ref]F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting.

Keywords: thyroid cancer,Positron emission tomography,18F-fluorodeoxyglucose


18F-fluorodeoxyglucose (18F-FDG) is a metabolic positron emission tomography/computed tomography (PET/CT) imaging agent. Its uptake depends on the glycolytic rate of the tumor. Differentiated thyroid cancers have a relatively low metabolic rate with better differentiation and radioactive iodine avidity. Dedifferentiated and other types of thyroid cancers however, show a higher glycolytic rate and 18F-FDG uptake. 18F-FDG PET/CT now has a common role in staging and restaging of thyroid cancers other than differentiated subtypes. Although some other 18F and Ga-68 labeled radiopharmaceuticals (FDOPA and Ga-68 labeled peptides) have been introduced for the same indications, 18F-FDG PET/CT is still the PET radiopharmaceutical of choice with its wide availability and lower cost, and other PET tracers now only have a complementary role. This paper aims to focus on the role of 18F-FDG PET/CT in less common tumors of the thyroid.

Medullary Thyroid Cancer

Medullary carcinoma is a neuroendocrine tumor of the thyroid originating from the parafollicular C cells. It is relatively infrequent and accounts for 5% of all thyroid cancers. It can present either as sporadic (75%) or familial (25%) forms. It characteristically secretes calcitonin (1).

Once medullary thyroid carcinoma is diagnosed by fine needle aspiration biopsy, neck ultrasound is recommended for preoperative lymph node assessment (2). For patients with preoperative calcitonin levels >500 pg/mL, additional radiologic imaging for evaluation of possible distant metastasis is indicated. Neck and chest CT, contrast-enhanced liver CT or magnetic resonance imaging (MRI), MRI of the axial skeleton and bone scintigraphy may be performed (3). 18F-FDG PET/CT is not routinely recommended at the staging of the disease (4).

Prognosis of the disease depends on the age and stage of the disease at diagnosis and the extent of the primary surgery performed. Additional factors for a better outcome in medullary thyroid cancer are female gender, well-differentiated histology, small tumor size, intracapsular tumor, lower levels of calcitonin in the postoperative period and absence of lymph node or distant metastasis. Although aggressive treatment strategies are followed in medullary thyroid cancer patients, persistent or recurrent disease is still frequently seen. Being the most sensitive tumor marker, serum calcitonin levels are usually elevated in recurrent cases. In approximately one third of the patients, carcinoembryonic antigen (CEA) is also increased. CEA elevation is also a prognostic determinant of advanced disease and dedifferentiation of the tumor (1,5). Biochemical recurrence leads the clinicians to investigate a tumor focus because tumor markers increase before radiologic examinations become positive. This is why identification of recurrent disease is quite problematic in disease management. In patients with postoperative calcitonin values <150 pg/mL, it is thought that recurrence is mostly related to locoregional disease and neck ultrasound is recommended. Serum calcitonin levels ≥150 pg/mL are more likely to be indicative of extensive disease (1). Functional imaging techniques have been found to be useful in this clinical setting (4,6,7,8). In a series of 55 medullary thyroid cancer patients with elevated calcitonin levels, the role of neck and abdomen USG, neck, chest, and abdomen CT, liver and whole-body MRI, bone scintigraphy, and 18F-FDG PET/CT were investigated comparatively. Conventional radiologic imaging methods were found to be more sensitive than 18F-FDG PET/CT for any site of tumor recurrence. They also found that maximum standardized uptake value (SUVmax) levels were higher in patients with progressive disease, but there was a significant overlap with the stable cases. The authors concluded that 18F-FDG PET/CT had a low prognostic value in medullary thyroid cancer (9). However, opposing results have been obtained in some other studies (10,11,12,13,14).

There are several studies reported in this era investigating the role of 18F-FDG PET/CT in recurrent medullary thyroid cancer patients with high levels of tumor markers. The sensitivity and specificity of 18F-FDG PET/CT is reported in a wide range (10,11,12,13,14). In a large series of 100 examinations, Diehl et al. (15) have reported a sensitivity of 78% and specificity of 79%. A recent meta-analysis of the published data by Treglia et al. (7) reviewed 24 major studies. Despite the heterogeneity in the definition of true negative and false negatives, examination techniques and inclusion criteria in these studies, on a per patient pooled analysis, the authors calculated a detection rate of 59% [95% confidence interval (CI): 54-63%] for 18F-FDG PET or PET/CT in patients with suspected recurrent medullary thyroid cancer. The detection rate of 18F-FDG PET/CT was higher in advanced disease (for serum calcitonin levels <150 ng/dL; detection rate: 40%, 95% CI: 29-52%, ≥150 ng/dL; detection rate: 64%, 95% CI: 59-70%, and ≥1000 ng/dL; 75%, 95% CI: 67-81%) (7). Undetectability of recurrent tumors at low levels of calcitonin and CEA was mainly attributed to small tumor size or microscopic disease (16).

Detection rates were also found to be higher in patients with lower calcitonin and CEA doubling time (for calcitonin doubling time <12 months, detection rate: 76%, and for CEA doubling time <24 months, detection rate: 91%) (7). This is reasonable, as the tumors with higher rate of proliferation are expected to have a higher metabolic rate and increased glucose consumption and thus higher detectability with 18F-FDG PET/CT (8). However, aggressive forms of medullary thyroid cancer are not always seen in the clinical setting, more indolent cases are sometimes encountered. Such lesions express lower levels of 18F-FDG uptake with SUVmax values, previously reported as a mean (±standard deviation): 3.76±1.79. Skoura et al. (17) also reported an interesting finding that the sensitivity of 18F-FDG PET/CT for medullary cancer recurrence in patients with multiple endocrine neoplasia (MEN) type 2A was significantly lower (23%), and for calcitonin levels <2000 pg/mL sensitivity was calculated as 0% in MEN 2A patients. Excluding the patients with MEN 2A, the overall sensitivity of 18F-FDG PET/CT raised from 44.1% to 50%. Thus, the authors concluded that 18F-FDG PET/CT was more reliable in sporadic or MEN 2B patients (17).

Site of metastasis has also been recently reported to be important for detectability by 18F-FDG PET/CT. De Luca et al. (18) have retrospectively analyzed metastatic medullary thyroid cancer patients who had undergone 18F-FDG PET/CT. They concluded that 18F-FDG PET/CT was primarily useful in lymph node involvement evaluation. Lung, liver or brain metastases could be missed due to the small size or low metabolic activity and as for skeletal metastases, detectability was limited to lytic metastases (18).

Recently other PET radiopharmaceuticals have been suggested for use in detection of recurrence in medullary thyroid cancer patients. 18F-DOPA is reported to have a higher sensitivity as compared to 18F-FDG PET/CT, especially in more indolent disease (15,19,20,21,22,23,24). A recent study by Archier et al. (25) has also revealed that 18F-DOPA PET/CT was reliable for a compartment based approach in lymph node involvement. Gallium-68 labeled peptides are also under scope for this use, especially to identify patients with tumors positive for somatostatin receptors, and thus candidates for radionuclide therapy (26,27). 18F-FDG PET/CT should not be considered as the first step in the diagnostic algorithm and must be spared for the cases with elevated levels of tumor markers but negative conventional imaging examinations. One must also keep in mind that functional imaging methods are complementary to each other in the way that they all have different routes of radiopharmaceutical uptake and that they work efficiently under different circumstances (7,28,29,30).

Anaplastic Thyroid Cancer

Anaplastic thyroid carcinoma is a rare malignancy constituting less than 2% of all thyroid cancers. It originates from follicular cells but is very poorly differentiated to have histopathologic characteristics of the differentiated tumors of the follicular cells. It shows a rapid growth and local invasion (31). Anaplastic thyroid carcinomas have a highly aggressive behavior with the worst prognosis among all thyroid cancers, given a median estimated survival of 6-8 months (1,32). This is why all anaplastic thyroid carcinomas are classified as Stage IV tumors and imaging methods for primary staging of the tumor includes CT of the head, neck, thorax, abdomen and pelvis as well as a bone scan or 18F-FDG PET/CT for identification of local or distant metastatic disease (1,33).

There is a limited number of studies evaluating 18F-FDG PET/CT in anaplastic thyroid carcinomas. However, 18F-FDG PET/CT may have a role in the follow-up of anaplastic thyroid cancer after primary surgery for detection of residual, recurrent, or metastatic disease (34,35). 18F-FDG PET/CT results are suggested to have an impact on the clinical management of anaplastic thyroid cancer. Anaplastic thyroid cancers have been reported to have a high glucose metabolism and thus, show a high 18F-FDG uptake. American Thyroid Association (ATA) have published a clinical management guideline on anaplastic thyroid cancer patients (4). 18F-FDG PET/CT has been recommended in anaplastic thyroid cancer at many steps in the management. It is recommended in the primary staging both for evaluation of lesion resectability and distant metastasis. Follow-up of anaplastic thyroid cancer patients is also successfully done by 18F-FDG PET/CT. It is recommended to be performed 3-6 months after therapy in patients either with or without persistent disease. 18F-FDG PET/CT is also recommended for distinction of anaplastic and differentiated thyroid cancer metastasis, based on the fact that anaplastic thyroid cancer metastases have a significantly higher SUVmax (4).

A few studies have investigated the possible prognostic role of 18F-FDG PET/CT in anaplastic thyroid cancer patients. As well as SUVmax, metabolic tumor volume has been introduced as a new index. Because some tumors show non-homogenous uptake, metabolic tumor volume has been shown to be a more valuable parameter in various tumors (36). In a series reported by Bogsrud et al. (37), PET has affected management in about 50% of anaplastic thyroid cancer patients. It was also found that SUVmax and metabolic tumor volume had a prognostic significance in these patients (37). Poisson et al. (38) similarly concluded that a SUVmax >18 and a 18F-FDG uptake volume >300 mL had a significantly worse 6 month survival.

Thyroid Lymphoma

Thyroid lymphoma is a rare disease with female dominance, mostly seen in the elderly. It constitutes 1-5% of all thyroid malignancies and 1-2.5% of all lymphomas (39).

Primary thyroid lymphoma is most commonly B-cell originated, and 60-80% of all cases have been reported to be diffuse-large B-cell lymphomas. They are considered to arise from follicular cells (40,41). About 30% of the thyroid lymphomas is extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). They are usually associated with the existence of Hashimoto’s thyroiditis (42). Autoimmune stimulation is thought to be responsible for disease development.

There are only a few reports on the role of 18F-FDG PET/CT in primary thyroid lymphomas, and most of them are case presentations. This is partly due to the infrequency of the disease. In a case report presented by Naswa et al. (43), the authors showed that 18F-FDG PET/CT was useful in staging and detecting therapy response in high-grade primary thyroid lymphoma in a 64-year-old female patient with a history of Hashimoto’s thyroiditis.

On 18F-FDG PET/CT, Hashimoto’s thyroiditis is a primary problem in the differential diagnosis of lymphomas as both entities may show intense diffuse 18F-FDG uptake. MALT lymphomas have been reported to show false-negative results in 18F-FDG PET imaging (44). However, a recent study in a large patient group revealed that SUVmax was significantly higher and CT density was lower in primary thyroid lymphoma as compared to chronic thyroiditis. The authors have thus suggested that 18F-FDG PET/CT may be helpful in distinguishing primary thyroid lymphoma from chronic thyroiditis (45). Similarly, a large series of thyroid lymphoma from a single center have been recently reported. Among the defined radiologic characteristics in this retrospective analysis, high SUVmax levels were remarkable. They reported a median SUVmax of 22.7 (range: 10.6-37.6) (46). Riedel’s thyroiditis, an IgG4-related disease, also presents with diffuse thyroidal uptake and should be kept in mind in differential diagnosis (47).

Metastatic Thyroid Cancer

Metastatic tumors of the thyroid are not uncommon (48,49). In autopsy series, the overall incidence of thyroid metastasis has been reported as 1.25% and as high as 24% in patients with known extensive disease metastatic to other sites (48,50). In a recent report of a large series, Hegerova et al. (49) listed the most common tumor types metastatic to the thyroid as follows: kidney (22%), lung (22%), and head and neck (12%). The role of 18F-FDG PET/CT in detection of metastatic tumors of thyroid is obscure. There are only a few case reports in the literature demonstrating the 18F-FDG uptake patterns of thyroid metastasis in other primary malignancies. Metastatic tumors of the thyroid are known to represent as thyroid masses, and thus they tend to show focal 18F-FDG uptake (51). However, Agrawal et al. (52) have recently defined heterogeneous thyroidal 18F-FDG uptake in a patient with known non-small cell lung carcinoma and multiple metastasis throughout the body. Any kind of unexpected thyroidal uptake in patients with known malignancies should be carefully evaluated for a possibility of thyroid metastasis.

Poorly Differentiated Thyroid Carcinoma

Poorly differentiated thyroid carcinoma histopathologically and behaviorally stands between differentiated thyroid carcinoma and anaplastic thyroid cancer. It does not appear de novo, differentiated tumors become de-differentiated by previously reported genetic alterations (53). Poorly differentiated thyroid carcinoma carries some characteristics of differentiation like thyroglobulin expression along with some features of anaplastic thyroid carcinoma like loss of iodine concentration ability and increased glucose transporter 1 (GLUT1) expression. The inverse relationship between iodine concentration and glucose uptake was defined as “flip-flop phenomenon” (54). Increased glucose uptake is partly related to the increased metabolic activity in highly proliferated tumor cells and Grabellus et al. (55) have also reported that de-differentiation was also accompanied by GLUT1 up-regulation. Increased glucose demand and GLUT expression provides high 18F-FDG uptake and detectability rates with 18F-FDG PET/CT. Compared to radioiodine scanning, poorly differentiated thyroid carcinoma are rather preferred to be screened by 18F-FDG PET/CT (56). It has a well documented role in all stages of disease evaluation. In preoperative staging, it has been reported to change management in 25% of the cases and that there was an inverse correlation between SUVmax levels and survival rates (57). In the postoperative period, Nascimento et al. (58) have recently recommended postoperative 18F-FDG PET/CT to be routinely performed in patients with aggressive histology. Usefulness of 18F-FDG PET/CT in the evaluation of therapy response was investigated. In anaplastic thyroid carcinoma patients who had undergone multimodal therapies, 18F-FDG PET/CT was suggested as a marker for treatment response (59).

Hürthle Cell Cancer

Hürthle cell cancer of the thyroid is a relatively uncommon form accounting for only 3.6% of all thyroid cancers (60). It has a worse prognosis and a higher tendency of metastases compared to other differentiated thyroid cancers (61,62,63). It especially has a more aggressive course when the primary tumor is widely invasive (64,65). It is known to have a lower radioiodine avidity (66,67). Thus, 18F-FDG PET/CT becomes a valuable alternative for imaging Hürthle cell cancer. The number of studies investigating the role of 18F-FDG PET/CT in Hürthle cell cancer is limited. A small report involving 12 patients found that 18F-FDG PET/CT was positive in 12 patients and that 18F-FDG PET/CT was the only positive imaging modality for localizing disease in 7/12 patients. Overall sensitivity was reported to be 92% and the patient management was changed by 18F-FDG PET/CT in 50% of all cases (68). In a heterogeneous group of thyroid cancer patients reported by Wang et al. (69), SUVmax and tumor volume were reported to have an important prognostic value in Hürthle cell cancer. Pryma et al. (70) reported 44 patients with Hürthle cell thyroid cancer. 18F-FDG PET/CT was performed for risk assessment after total thyroidectomy in patients with elevated thyroglobulin levels. They calculated the overall sensitivity and specificity of 18F-FDG PET/CT as 95% (70).

Thyroid Incidentaloma

Thyroid incidentalomas are defined as thyroid lesions detected by an imaging study that were not previously suspected or detected in an asymptomatic patient. Incidental thyroidal 18F-FDG uptake is not uncommon in oncological 18F-FDG PET/CT studies performed for any other malignancy. As the use of 18F-FDG PET/CT in staging, restaging of other malignancies and evaluation of therapy response increased, the frequency of incidental 18F-FDG uptake has also increased. The incidence has been reported as 0.2-8.9% (71). There are many studies in the literature investigating the clinical significance of thyroidal 18F-FDG uptake. Overall malignancy rate in an incidentally detected thyroid lesion is in a wide range:13-59% (72) .The pattern of 18F-FDG uptake is important for evaluation of the etiology of the uptake. Diffuse thyroidal 18F-FDG uptake has been generally reported to be related to thyroiditis and autoimmune process, and it is seen in about 0.6-3.3% of all 18F-FDG PET/CT studies (73).

The frequency of focal incidentalomas are 0.2-10%. The risk of malignancy is known to be higher in the focal 18F-FDG uptake group as compared to diffuse thyroidal 18F-FDG uptake. However, the malignancy prevalence in patients who present with focal thyroidal 18F-FDG uptake differs in a wide range in the literature (8-64%) (74).

The most common type of thyroid cancer detected in thyroid incidentalomas on 18F-FDG PET/CT is papillary thyroid cancer and follicular type papillary thyroid cancer (81.1%). Primary thyroid lymphoma and thyroidal metastasis of other malignancies account for 4.1% of these (75). In another series reported by Agrawal et al. (76) however, the percentage of metastatic thyroid cancer or thyroid lymphoma incidentally detected were 44.4%. Some investigators have proposed that incidental thyroid malignancies tend to have a more aggressive histologic subtype and a higher tumor grade, and that they should be evaluated more carefully (77). This can be related with the increased 18F-FDG avidity in de-differentiated cancers, as described above.

First step in the evaluation of incidental thyroid nodules is thyroid ultrasound. But two studies revealed that 18F-FDG avid thyroid nodules are indicative of malignancy regardless of suspicious findings on ultrasound (78,79). Therefore, fine needle aspiration biopsy is strongly recommended in metabolically active thyroid nodules (80). The ATA has recently published a management guideline in thyroid nodules in adult patients. Thyroid incidentalomas detected by 18F-FDG PET/CT was also mentioned, and they recommended fine-needle aspiration biopsy for focal 18F-FDG uptake corresponding to a nodule on thyroid ultrasonography. Diffuse 18F-FDG uptake, accompanied by sonographic and clinical evidence of thyroiditis was not a necessity for histopathologic examination (81).

There have been many efforts to determine a SUVmax cut-off for thyroidal 18F-FDG uptake, above which will indicate malignancy. It is obvious that the SUVmax is statistically significantly high in malignant lesions but there is no safe cut-off value to guide management. In a study by Stangierski et al. (82), a total of 82 patients with focal 18F-FDG uptake in the thyroid were further investigated by fine needle aspiration biopsy. The mean SUVmax for benign lesions was calculated as 3.2 and for malignant lesions as 7.1. Because the range of SUVmax was between 1.4-17.5 in benign lesions and between 1.8-33.6 in malignant lesions, there was a wide overlap between the two subsets, and therefore no cut-off was reliable. Investigators also found out that for malignant lesions detected by 18F-FDG PET/CT, there was a significant correlation between the diameter of the nodule and SUVmax. The authors have thus suggested a cautious examination in small lesions even if they have low 18F-FDG uptake.

SUVmax is not the only parameter to evaluate preoperative risk in incidental thyroid malignancies. Kim et al. (83) have investigated the role of total lesion glycolysis and metabolic tumor volume in the prediction of lateral lymph node metastasis in patients with incidentally detected differentiated thyroid carcinoma. They found out that these volume-based PET functional parameters were significant in predicting lateral lymph node metastasis. Risk stratification with these parameters may be of clinical value if supported by larger studies (83).

Functional imaging provides certain advantages which cannot be obtained by conventional anatomical imaging methods. In nuclear medicine practice, 18F-FDG now has a major place as it is a nonspecific marker of increased metabolism. Differentiated thyroid tumors usually have a silent course, while other tumors of the thyroid show a variable presentation. Dedifferentiation, poor differentiation and anaplastic characters of these tumors lean high 18F-FDG avidity. Considering all the aforementioned data, we recommend 18F-FDG PET/CT in both initial evaluation and follow-up of undifferentiated thyroid cancers. Medullary thyroid carcinoma, the neuroendocrine tumor of the thyroid, has other functional imaging options than 18F-FDG PET/CT like somatostatin receptor imaging. But, in advanced cases, especially with high levels of tumor markers, the tumor is most likely to be dedifferentiated and metabolic imaging, to the best of our experience, is the most accurate way to evaluate these patients. Thyroid lymphoma is a rare clinical condition and we have a limited clinical expertise, but recent publications revealed that this tumor presents with high metabolic rate and 18F-FDG PET/CT has a definitive role for thyroid lymphoma, primarily in cases with unexpected findings like rapidly growing neck mass, compression symptoms and weight loss.


In medullary thyroid carcinoma; 18F-FDG PET/CT is not routinely recommended in the primary staging of the disease, but it has been reported to be useful in the follow-up to evaluate high levels of calcitonin and CEA. Detection rates have been found to be higher in shorter tumor marker doubling times and in sporadic cases as compared to MEN syndromes. Its prognostic significance is still under debate in medullary thyroid cancer. Limited data published on anaplastic thyroid carcinomas revealed that 18F-FDG PET/CT may have a role in both staging and follow-up of these patients. SUVmax and metabolic tumor volume values seem to have a prognostic importance. 18F-FDG PET/CT can be of value in the differential diagnosis of primary thyroid lymphoma and thyroiditis. Metastatic tumors of the thyroid are not as uncommon as previously assumed, so special attention should be paid on thyroidal 18F-FDG uptake in patients with known malignancies. In poorly differentiated thyroid cancers, it is reasonable to use 18F-FDG PET/CT for follow-up due to high 18F-FDG uptake and metabolic tumor rate. Hürthle cell cancer is a rather rare histopathologic subtype of thyroid cancer with less iodine avidity. 18F-FDG PET/CT seems to have an important role with high detection rates and sensitivity-specificity in Hürthle cell cancer. Incidental thyroidal 18F-FDG uptake necessitates further clarification, especially if focal uptake corresponds to a sonographically evident thyroid nodule.


Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: Mine Araz, Design: Mine Araz, Data Collection or Processing: Derya Çayır, Analysis or Interpretation: Mine Araz, Derya Çayır, Literature Search: Derya Çayır, Writing: Mine Araz.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

1.    Pitt SC, Moley JF. Medullary, Anaplastic, and Metastatic Cancers of the Thyroid. Semin Oncol 2010;37:567-579.
2.    Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:475-485.
3.    Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2655-2663.
4.    American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
5.    Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):110-119.
6.    Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the Management of Thyroid Cancers. AJR Am J Roentgenol 2014;202:1316-1329.
7.    Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 2012;42:535-545.
8.    Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hör G. Metabolic (PET) and receptor (SPET) imaging of well and less well-differentiated tumours: comaprison with the expression of the Ki-67 antigen. Nucl Med Commun 1998:19:641-647.
9.    Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:4185-4190.
10.    Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfurst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009;19:1425-1434.
11.    Kauhanen S, Schalin-Jantti C, Seppanen M, Kajander S, Virtanen S, Schildt J, Lisinen I, Ahonen A, Heiskanen I, Vaisanen M, Arola J, Korsoff P, Ebeling T, Sane T, Minn H, Valimaki MJ, Nuutila P. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011;52:1855-1863.
12.    Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorinefluorodihydroxyphenyl alanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010;20:527-533.
13.    Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, Ambrosini V, Cremonini N, Santimaria M, Versari A, Fanti S, Giordano A, Rufini V. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012;39:569-580.
14.    Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC, van der Horst-Schrivers AN, Brouwers AH, Links TP. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012;53:1863-1871.
15.    Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28:1671-1676.
16.    Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, Shaha AR, Tuttle RM, Shah JP, Larson SM. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007;48:501-507.
17.    Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, Exarhos D, Alevizaki M. Correlation between calcitonin levels and [18F] FDGPET/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer. ISRN Endocrinol 2012;2012:37523.
18.    De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S. Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Ann Nucl Med 2016;30:234-241.
19.    Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB. Comparison of 68Ga-DOTATATE and 18F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:49-57.
20.    Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007;92:4590-4597.
21.    Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1604-1609.
22.    Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT. Mol Imaging Biol 2007;9:72-77.
23.    Czepczynski R, Kosowicz J, Ziemnicka K, Mikolajczak R, Gryczynska M, Sowinski J. The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma. Endokrynol Pol 2006;57:431-435.
24.    Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804.
25.    Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, Schneegans O, Mundler O, Adbullah AE, Sebag F, Imperiale A, Taieb D. 18F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2016;43:1027-1033.
26.    Volkan-Salancı B, Kıratlı PÖ. Nuclear medicine in thyroid diseases in pediatric and adolescent patients. Mol Imaging Radionucl Ther 2015;24:47-59.
27.    Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, Adalet I. Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun 2015;36:242-250.
28.    Czepczynski R, Parisella MG, Kosowicz J, Mikolajczak R, Ziemnicka K, Gryczynska M, Sowinski J, Signore A. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1635-1645.
29.    Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Valimaki M, Nuutila P. The clinical value of [18F]fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009;16:255-265.
30.    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-87.
31.    Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254-260.
32.    Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008;33:341-357.
33.    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010:87–96.
34.    Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, Goerres GW. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113:888-891.
35.    Jadvar H, Fischman AJ. Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 1999;2:153-158.
36.    Soydal C, Yüksel C, Küçük NÖ, Okten I, Ozkan E, Doğanay Erdoğan B. Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients. Mol Imaging Radionucl Ther 2014;23:12-15.
37.    Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008;18:713-719.
38.    Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:2277-2285.
39.    Ansell SM, Grant CS, HAbermann TM. Primary Thyroid lymphoma. Semin Oncol 1999;26:316-323.
40.    Skarsgard ED, Connors JM, Robins RE. A current analysis of primary lymphoma of the thyroid. Arch Surg 1991;126:1199-1203.
41.    Junor EJ, Paul J, Reed NS. Primary non-Hodgkin’s lymphoma of the thyroid. Eur J Surg Oncol 1992;18:313-321.
42.    Burke JS. Are there site-specific differences among the MALT lymphomas--morphologic, clinical? Am J Clin Pathol 1999;111(Suppl 1):133-143.
43.    Naswa N, Sharma P, Nazar AH, Mohapatra TK, Bal C, Kumar R. (18)F-FDG PET/CT for initial assessment and response monitoring in a case of high grade primary lymphoma of the thyroid gland: A case report and review of literature. Indian J Nucl Med 2014;29:94-96.
44.    Mikosch P, Würtz FG, Gallowitsch HJ, Kresnik E, Lind P. F-18-FDG-PET in a patient with Hashimoto’s thyroiditis and MALT lymphoma recurrence of the thyroid. Wien Med Wochenschr 2003;153:89-92.
45.    Nakadate M, Yoshida K, Ishii A, Koizumi M, Tochigi N, Suzuki Y, Ryu Y, Nakagawa T, Umehara I, Shibuya H. Is 18F-FDG PET/CT useful for distinguishing between primary thyroid lymphoma and chronic thyroiditis? Clin Nucl Med 2013;38:709-714.
46.    Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas BJC, Habermann TM, Fatourechi V, Stan M. Clinical presentation and diagnostic challenges of thyroid lymphoma: a cohort study. Thyroid 2016;26:1061-1067.
47.    Mansber R, Bency R, Shen L, Bui C, Park K. Riedel’s Thyroiditis With Intense FDG uptake demonstrated on FDG PET/CT. Mol Imaging Radionucl Ther 2015;24:29-31.
48.    Nakhjavani MK, Gharib H, Goellner JR, van Heerden JA. Metastasis to the thyroid gland: A report of 43 cases. Cancer 1997;79:574-578.
49.    Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H. Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. Am J Clin Oncol 2015;38:338-342.
50.    Berge T, Lundberg S. Cancer in Malmo 1958-1969: an autopsy study. Acta Pathol Microbiol Scand 1977;(Suppl)260:1-235.
51.    Treglia G, Bongiovanni M, Paone G, Ceriani L, Giovanella L. Metastatic undifferentiated spindle cell sarcoma of the thyroid gland evaluated by 18F-FDG PET/CT. Clin Nucl Med 2015;40:e208-10.
52.    Agrawal K, Weaver J, Mohan HK. Metastasis to the thyroid from non-small cell carcinoma of the lung: findings in (18)F-FDG PET/CT study. Endocrine 2015;48:720-721.
53.    Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 2004;15:319-327.
54.    Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-1472.
55.    Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37:121-127.
56.    Muros de Fuentes MA, Mitjavila Casanovas M, Estorch Cabrera M, Lecumberri Santamaria B, Navarro Gonzalez E. Usefulness of 18F-FDG PET/CT in thyroid carcinoma. Rev Esp Med Nucl Imagen Mol 2016;35:186-192.
57.    Palaniswamy SS, Subramanyam P. Diagnostic utility of PETCT in thyroid malignancies: an update. Ann Nucl Med 2013;27:681-693.
58.    Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015;25:437-444.
59.    Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Ghuzlan AA, Hartl D, Deutsch E, Deandreis D, Lumbroso J, Tao Y, Schlumberger M, Blanchard P. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplasticthyroid cancer. Oral Oncol 2015;51:370-375.
60.    Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996: U.S. and German Thyroid Cancer Study Group-an American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-217.
61.    Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hurthle cell carcinoma. Surgery 1995;118:711-714.
62.    Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL J Otorhinolaryngol Relat Spec 2001;63:243-249.
63.    Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996;172:692-694.
64.    Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP, Brennan MF, Shaha AR, Singh B. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 2001;19:2616-2625.
65.    Stojadinovic A, Hoos A, Ghossein RA, Urist MJ, Leung DH, Spiro RH, Shah JP, Brennan MF, Singh B, Shaha AR. Hurthle cell carcinoma: a 60-year experience. Ann Surg Oncol 2002;9:197-203.
66.    Yutan E, Clark OH. Hurthle cell carcinoma. Curr Treat Options Oncol 2001;2:331-335.
67.    Yen TC, Lin HD, Lee CH, Chang SL, Yeh SH. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans. Eur J Nucl Med 1994;21:980-983.
68.    Lowe VJ, Mullan BP, Hay ID, McIver B, Kasperbauer JL. 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med 2003;44:1402-1406.
69.    Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-1113.
70.    Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47:1260-1266.
71.    Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 2012;97:3866-3875.
72.    Gavriel H, Tang A, Eviatar E, Chan SW. Unfolding the role of PET FDG scan in the management of thyroid incidentaloma in cancer patients. Eur Arch Otorhinolaryngol 2015;272:1763-1768.
73.    Liu Y. Clinical significance of thyroid uptake on F18- fluorodeoxyglucose positron emission tomography. Ann Nucl Med 2009;23:17-23.
74.    Bertagna F, Treglia G, Piccardo A, Giovannini E, Bosio G, Biasiotto G, Bahij el K, Maroldi R, Giubbini R. F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine 2013;43:678-685.
75.    Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012;22:918-925.
76.    Agrawal K, Weaver J, Ul-Hassan F, Jeannon JP, Simo R, Carroll P, Hubbard JG, Chandra A, Mohan HK. Incidence and Significance of Incidental Focal Thyroid Uptake on (18)F-FDG PET Study in a Large Patient Cohort: Retrospective Single-Centre Experience in the United Kingdom. Eur Thyroid J 2015;4:115-122.
77.    Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Shaha AR. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007;14:3210-3215.
78.    Kwak JY, Kim EK, Yun M, Cho A, Kim MJ, Son EJ, Oh KK. Thyroid incidentalomas identified by 18F-FDG PET: sonographic correlation. AJR Am J Roentgenol 2008;191:598-603.
79.    Choi JS, Choi Y, Kim EK, Yoon JH, Youk JH, Han KH, Moon HJ, Kang WJ, Kwak JY. A risk-adapted approach using US features and FNA results in the management of thyroid incidentalomas identified by 18F-FDG PET. Ultraschall Med 2014;35:51-58.
80.    Hoang JK, Langer JE, Middleton WD, Wu CC, Hammers LW, Cronan JJ, Tessler FN, Grant EG, Berland LL. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol 2015;12:143-150.
81.    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
82.    Stangierski A, Woliński K, Czepczyński R, Czarnywojtek A, Lodyga M, Wyszomirska A, Janicka-Jedyńska M, Bączyk M, Ruchała M. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One 2014;9:e109612.
83.    Kim BH, Kim SJ, Kim K, Kim H, Kim SJ, Kim WJ, Jeon YK, Kim SS, Kim YK, Kim IJ. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med 2015;29:721-729.